Samil Pharmaceutical Co.,Ltd (000520.KS)
KRW 13130.0
(-3.95%)
KRW 13130.0
(-3.95%)
| Year | EBITDA | EBITDA Growth |
|---|---|---|
| 2023 | 11.82 Billion KRW | 21.78% |
| 2022 | 10.3 Billion KRW | 68.42% |
| 2021 | 5.11 Billion KRW | -48.3% |
| 2020 | 11.32 Billion KRW | 17.33% |
| 2019 | 8.81 Billion KRW | 607.55% |
| 2018 | -2.05 Billion KRW | -138.77% |
| 2017 | 4.94 Billion KRW | -30.65% |
| 2016 | 6.76 Billion KRW | 42.62% |
| 2015 | 4.64 Billion KRW | 186.67% |
| 2014 | -5.42 Billion KRW | -132.32% |
| 2013 | 1.54 Billion KRW | 580.3% |
| 2012 | 735.53 Million KRW | 188.85% |
| 2011 | -2.37 Billion KRW | -135.51% |
| 2010 | 8.83 Billion KRW | -44.88% |
| 2009 | 15.12 Billion KRW | 38.5% |
| 2008 | 10.57 Billion KRW | -16.62% |
| 2007 | 13.33 Billion KRW | 0.0% |
| Year | EBITDA | EBITDA Growth |
|---|---|---|
| 2024 Q2 | 2.45 Billion KRW | -28.59% |
| 2024 Q1 | 3.43 Billion KRW | -2.73% |
| 2023 FY | - KRW | 21.78% |
| 2023 Q4 | 3.52 Billion KRW | -80.3% |
| 2023 Q2 | 3.3 Billion KRW | 25.25% |
| 2023 Q1 | 2.64 Billion KRW | 2894.96% |
| 2023 Q3 | 17.9 Billion KRW | 441.52% |
| 2022 Q4 | -94.46 Million KRW | -104.35% |
| 2022 FY | - KRW | 68.42% |
| 2022 Q2 | 4.06 Billion KRW | 13.78% |
| 2022 Q3 | 2.17 Billion KRW | -46.53% |
| 2022 Q1 | 3.57 Billion KRW | 6454.67% |
| 2021 Q2 | 1.32 Billion KRW | -55.87% |
| 2021 Q3 | 1.5 Billion KRW | 13.69% |
| 2021 Q1 | 2.99 Billion KRW | 186.35% |
| 2021 FY | - KRW | -48.3% |
| 2021 Q4 | -56.19 Million KRW | -103.74% |
| 2020 Q3 | 2.24 Billion KRW | -27.68% |
| 2020 FY | - KRW | 17.33% |
| 2020 Q1 | 4.62 Billion KRW | 112.5% |
| 2020 Q2 | 3.09 Billion KRW | -32.99% |
| 2020 Q4 | 1.04 Billion KRW | -53.29% |
| 2019 Q3 | 1.46 Billion KRW | -35.69% |
| 2019 Q4 | 2.17 Billion KRW | 48.7% |
| 2019 Q2 | 2.27 Billion KRW | -37.2% |
| 2019 Q1 | 3.62 Billion KRW | 456.79% |
| 2019 FY | - KRW | 607.55% |
| 2018 Q3 | -1 Billion KRW | -662.03% |
| 2018 FY | - KRW | -138.77% |
| 2018 Q4 | -1.01 Billion KRW | -1.22% |
| 2018 Q2 | -131.65 Million KRW | -157.49% |
| 2018 Q1 | 229 Million KRW | -88.23% |
| 2017 FY | - KRW | -30.65% |
| 2017 Q3 | -659.36 Million KRW | -143.42% |
| 2017 Q4 | 1.94 Billion KRW | 394.99% |
| 2017 Q2 | 1.51 Billion KRW | -25.06% |
| 2017 Q1 | 2.02 Billion KRW | -18.28% |
| 2016 Q1 | 1.03 Billion KRW | 142.62% |
| 2016 Q4 | 2.48 Billion KRW | 77.88% |
| 2016 FY | - KRW | 42.62% |
| 2016 Q3 | 1.39 Billion KRW | 98.01% |
| 2016 Q2 | 704.11 Million KRW | -31.95% |
| 2015 Q1 | 1.14 Billion KRW | 135.74% |
| 2015 Q4 | 426.47 Million KRW | -17.09% |
| 2015 Q3 | 514.39 Million KRW | 373.7% |
| 2015 Q2 | 108.59 Million KRW | -90.49% |
| 2015 FY | - KRW | 186.67% |
| 2014 Q3 | -2.72 Billion KRW | -7.41% |
| 2014 Q4 | -3.19 Billion KRW | -17.19% |
| 2014 FY | - KRW | -132.32% |
| 2014 Q1 | -144.51 Million KRW | -101.12% |
| 2014 Q2 | -2.53 Billion KRW | -1655.36% |
| 2013 Q4 | 12.86 Billion KRW | 2142.46% |
| 2013 Q1 | 1.08 Billion KRW | 185.36% |
| 2013 Q2 | 437.14 Million KRW | -59.85% |
| 2013 FY | - KRW | 580.3% |
| 2013 Q3 | -629.99 Million KRW | -244.11% |
| 2012 Q3 | -282.41 Million KRW | -132.23% |
| 2012 Q4 | -1.27 Billion KRW | -351.68% |
| 2012 FY | - KRW | 188.85% |
| 2012 Q1 | 1.39 Billion KRW | 0.0% |
| 2012 Q2 | 876.29 Million KRW | -37.1% |
| 2011 Q4 | - KRW | 100.0% |
| 2011 FY | - KRW | -135.51% |
| 2011 Q3 | -471.47 Million KRW | -89.16% |
| 2011 Q2 | -249.25 Million KRW | -108.18% |
| 2011 Q1 | 3.04 Billion KRW | 16.91% |
| 2010 FY | - KRW | -44.88% |
| 2010 Q3 | 765.29 Million KRW | -74.71% |
| 2010 Q4 | 2.6 Billion KRW | 240.37% |
| 2010 Q2 | 3.02 Billion KRW | 75.32% |
| 2010 Q1 | 1.72 Billion KRW | 271.65% |
| 2009 Q4 | -1 Billion KRW | -106.07% |
| 2009 Q1 | 630.48 Million KRW | 144.08% |
| 2009 Q3 | 16.56 Billion KRW | 1238.12% |
| 2009 Q2 | -1.45 Billion KRW | -330.91% |
| 2009 FY | - KRW | 38.5% |
| 2008 Q1 | 6.32 Billion KRW | 391.83% |
| 2008 Q3 | 791.56 Million KRW | -83.82% |
| 2008 FY | - KRW | -16.62% |
| 2008 Q2 | 4.89 Billion KRW | -22.69% |
| 2008 Q4 | -1.43 Billion KRW | -280.69% |
| 2007 Q1 | 5.85 Billion KRW | 0.0% |
| 2007 Q2 | 5.13 Billion KRW | -12.26% |
| 2007 Q3 | 3.36 Billion KRW | -34.59% |
| 2007 FY | - KRW | 0.0% |
| 2007 Q4 | -2.16 Billion KRW | -164.49% |
| Name | EBITDA | EBITDA Difference |
|---|---|---|
| Yuyu Pharma, Inc. | 4.85 Billion KRW | -143.455% |
| Dong-A Socio Holdings Co., Ltd. | 141.36 Billion KRW | 91.633% |
| Ildong Holdings Co., Ltd. | -64.03 Billion KRW | 118.471% |
| HANDOK Inc. | 35.06 Billion KRW | 66.27% |
| Kukje Pharma Co., Ltd. | -1.03 Billion KRW | 1241.052% |
| Yuhan Corporation | 127.43 Billion KRW | 90.718% |
| Dong-A ST Co., Ltd. | 37.52 Billion KRW | 68.477% |
| SAMSUNG PHARM. Co., LTD. | -21.68 Billion KRW | 154.538% |
| Hanmi Pharm. Co., Ltd. | 323.33 Billion KRW | 96.342% |
| Hanall Biopharma Co.,Ltd | 4.99 Billion KRW | -137.016% |
| Ilyang Pharmaceutical Co.,Ltd | 15.11 Billion KRW | 21.764% |
| Dong Sung Bio Pharm.Co.,Ltd. | 3.42 Billion KRW | -245.745% |
| MYUNGMOON Pharm co.,Ltd | 4.52 Billion KRW | -161.308% |
| Hana Pharm Co., Ltd. | 35.48 Billion KRW | 66.669% |
| Yuyu Pharma, Inc. | 4.85 Billion KRW | -143.455% |
| Ilsung Pharmaceuticals Co., Ltd. | -18.47 Billion KRW | 164.032% |
| REYON Pharmaceutical Co., Ltd. | 6.55 Billion KRW | -80.441% |
| Aprogen pharmaceuticals,Inc. | -49.29 Billion KRW | 123.996% |
| JW Holdings Corporation | 187.88 Billion KRW | 93.705% |
| Ildong Pharmaceutical Co., Ltd. | -51.22 Billion KRW | 123.088% |
| Chong Kun Dang Pharmaceutical Corp. | 283.62 Billion KRW | 95.83% |
| JW Pharmaceutical Corporation | 89.22 Billion KRW | 86.743% |
| Shin Poong Pharm.Co.,Ltd. | -37.06 Billion KRW | 131.91% |
| Hyundai Pharmaceutical Co., Ltd. | 13.2 Billion KRW | 10.46% |
| Jeil Pharmaceutical Co.,Ltd | 18.65 Billion KRW | 36.596% |
| Yuyu Pharma, Inc. | 4.85 Billion KRW | -143.455% |
| Kwang Dong Pharmaceutical Co., Ltd. | 54.97 Billion KRW | 78.484% |
| Daewoong pharmaceutical Co.,Ltd | 164.91 Billion KRW | 92.828% |
| JW Pharmaceutical Corporation | 89.22 Billion KRW | 86.743% |
| Yuhan Corporation | 127.43 Billion KRW | 90.718% |
| Jeil Pharma Holdings Inc | 33.47 Billion KRW | 64.668% |
| Yungjin Pharm. Co., Ltd. | 7.64 Billion KRW | -54.616% |
| Suheung Co., Ltd. | 77.02 Billion KRW | 84.645% |
| JW Pharmaceutical Corporation | 89.22 Billion KRW | 86.743% |
| Samjin Pharmaceuticals Co., Ltd. | 36.63 Billion KRW | 67.714% |
| Korea United Pharm Inc. | 70.78 Billion KRW | 83.289% |
| CKD Bio Corp. | -1.63 Billion KRW | 825.438% |
| Daewon Pharmaceutical Co., Ltd. | 49.79 Billion KRW | 76.246% |
| Dongwha Pharm.Co.,Ltd | 32.56 Billion KRW | 63.675% |
| Whan In Pharm Co.,Ltd. | 36.81 Billion KRW | 67.868% |
| Shin Poong Pharm.Co.,Ltd. | -37.06 Billion KRW | 131.91% |
| Chong Kun Dang Holdings Corp. | 62.28 Billion KRW | 81.01% |
| Boryung Corporation | 114.28 Billion KRW | 89.651% |
| Bukwang Pharmaceutical Co., Ltd. | -30.56 Billion KRW | 138.693% |
| Ilyang Pharmaceutical Co.,Ltd | 15.11 Billion KRW | 21.764% |
| JW Lifescience Corporation | 50.82 Billion KRW | 76.73% |